Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 84 publications
ARMED: an Australian cohort retrospective observational study to understand motivations for switching and clinical outcomes of individuals switching to dolutegravir/lamivudine.
Journal: Sexual health
Published: February 05, 2026
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial.
Journal: Lancet (London, England)
Published: January 22, 2026
Mosaic chromosomal alterations are suppressed in older adults with HIV.
Journal: Communications biology
Published: October 13, 2025
Australian guidelines for anal cancer screening using anal human papillomavirus testing with cytology triage in people living with HIV.
Journal: HIV medicine
Published: August 24, 2025
Switch to fixed-dose doravirine (100 mg) and islatravir (0·25 mg) once daily in virologically suppressed adults with HIV-1 on oral antiretroviral therapy: 48-week results of a phase 3, multicentre, randomised, open-label, non-inferiority trial.
Journal: Lancet (London, England)
Published: August 04, 2025
Efficacy and Safety of Bictegravir Plus Lenacapavir: 48-Week Outcomes in People With HIV-1 Who Are Virologically Suppressed on Complex Antiretroviral Regimens at Baseline.
Journal: Open forum infectious diseases
Published: June 25, 2025
Anal Cancer Screening in People Living With HIV: A Pilot Study of Primary HPV Screening With Triage Use of p16/Ki67 Dual Stain.
Journal: Journal of acquired immune deficiency syndromes (1999)
Published: December 17, 2024
Control and Elimination of Hepatitis C Virus Among People With HIV in Australia: Extended Follow-up of the CEASE Cohort (2014-2023).
Journal: Open forum infectious diseases
Published: October 28, 2024
Monitoring and reporting of adverse effects of testosterone prescribing for gender affirmation at general practice clinics - Data from the PUSH! Audit.
Journal: International journal of transgender health
Published: October 28, 2024
Safety and immunogenicity of a modified mRNA-lipid nanoparticle vaccine candidate against COVID-19: Results from a phase 1, dose-escalation study.
Journal: Human vaccines & immunotherapeutics
Published: October 18, 2024
4CMenB Breadth of Immune Response, Immunogenicity, and Safety: Results From a Phase 3 Randomized, Controlled, Observer Blind Study in Adolescents and Young Adults.
Journal: Open forum infectious diseases
Published: July 04, 2024
Last Updated: 09/26/2026